You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌禮製藥(01672.HK)口服FASN抑制劑ASC40三期試驗達到所有終點
阿思達克 06-04 08:42
歌禮製藥(01672.HK)宣布,口服小分子脂肪酸合成(酉每)(FASN)抑制劑產品地尼法司他(ASC40),在治療中重度尋常性痤瘡的三期臨床試驗中,達到所有主要、關鍵次要及次要終點。該試驗是一項在中國開展的隨機、雙盲、安慰劑對照、多中心的臨床試驗,旨在評估地尼法司他每日一次口服片在480例中重度尋常性痤瘡患者中的安全性和療效。 歌禮創始人、董事會主席兼首席執行官吳勁梓表示,對試驗頂線數據非常滿意,認為產品在治療成功方面表現出色,且總皮損、炎性皮損和非炎性皮損均顯著下降,將很快向中國國家藥品監督管理局(NMPA)遞交此創新療法。 歌禮已從Sagimet Biosciences Inc.(SGMT.US)獲得地尼法司他的大中華區獨家授權。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account